Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) traded down 6.2% during mid-day trading on Friday . The stock traded as low as $13.31 and last traded at $13.61, with a volume of 252,810 shares. The stock had previously closed at $14.51.

Several equities research analysts have issued reports on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. Cowen and Company reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. Mizuho raised Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 target price for the company in a research note on Thursday, June 16th. Noble Financial assumed coverage on Adamas Pharmaceuticals in a research note on Friday, June 17th. They issued a “buy” rating and a $25.00 target price for the company. Finally, JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $32.00.

The firm’s market capitalization is $295.86 million. The company’s 50-day moving average price is $15.43 and its 200-day moving average price is $15.81.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.11. On average, equities research analysts forecast that Adamas Pharmaceuticals Inc. will post ($3.17) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent reporting period.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.